Drug intelligence / Profile preview

PF-06678552

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-06678552 is an investigational small molecule compound developed for the treatment of hypercholesterolemia. It has been evaluated in clinical studies to assess its safety and tolerability in healthy subjects, with its primary therapeutic area being endocrinology and metabolic diseases, specifically targeting elevated cholesterol levels. The drug was initially developed by Pfizer.

Beyond the preview

Go deeper on PF-06678552.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06678552.

Explore the full profile